Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines
Cynthia M. Rohde, Claudia Lindemann, Michael A. Giovanelli, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 417-417
Open Access | Times Cited: 23

Showing 23 citing articles:

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity
Liusheng Wu, Xiaoqiang Li, Xinye Qian, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 186-186
Open Access | Times Cited: 53
sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models
Cheng Chang, Harsh Patel, Annette Ferrari, et al.
Vaccine (2025) Vol. 51, pp. 126883-126883
Closed Access | Times Cited: 1
Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis
Wanqian Xu, Weigang Ren, Tongxin Wu, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1118-1118
Open Access | Times Cited: 18
Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data
Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 6
Roadmap to discovery and early development of an mRNA loaded LNP formulation for liver therapeutic genome editing
Annette Bak, Liping Zhou, Joanna Rejman, et al.
Expert Opinion on Drug Delivery (2025)
Closed Access
BioNTech/Pfizer (BNT162b2) COVID-19 mRNA vaccine: manufacturing, immunogenicity, efficacy and safety
Esraa Alkhalil, Bashar Jarad, Tala Al Saleh, et al.
Prospects in Pharmaceutical Sciences (2025) Vol. 23, Iss. 1, pp. 31-46
Open Access
Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects
Zijing Wei, Shuai Zhang, Xingya Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat
Juan Liu, Xicheng Chen, C. C. Chen, et al.
Toxicology (2025), pp. 154107-154107
Closed Access
Nanoparticle-Mediated Embryotoxicity: Mechanisms of Chemical Toxicity and Implications for Biological Development
Biswajeet Acharya, Amulyaratna Behera, Srikanta Moharana, et al.
Chemical Research in Toxicology (2025)
Closed Access
Proceedings of the 2023 Annual Scientific Meeting of the French Society of Toxicologic Pathology (SFPT) on Preclinical Development and Therapeutic Applications of mRNA-Based Technologies
Pierluigi Fant, Sébastien Laurent, Paul Désert, et al.
Toxicologic Pathology (2025)
Closed Access
Local Tolerability of Biodegradable Long-Acting Injectables
Esther Sutter, Kuno Wuersch, Helen Booler
(2025), pp. 221-243
Closed Access
Comparing the immune response of mRNA-based, inactivated COVID-19 and seasonal influenza vaccines and their effects on submandibular glands and associated lymph nodes in albino rats: biochemical, histological and immunohistochemical analysis
Nermeen AbuBakr, Rabab Mubarak, Tahany Haggag, et al.
Journal of Stomatology Oral and Maxillofacial Surgery (2025), pp. 102393-102393
Closed Access
A Similar Nonclinical Safety Evaluation of Prev(e)nar 13 in a Multi-Dose Formulation Containing the Preservative 2-Phenoxyethanol
Yana Chervona, Wen‐Hui Shen, Shambhunath Choudhary, et al.
Vaccines (2025) Vol. 13, Iss. 5, pp. 486-486
Open Access
Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis
Ziyi Chen, Zhiliang Liu, Yali Feng, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
Teresa Hauguel, Amy Sharma, Emily Mastrocola, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 3
An Industry Perspective on the Use of Novel Excipients in Lipid Nanoparticles—Nonclinical Considerations
Lorrene A. Buckley, Jessica E. Sutherland, Prachi Borude, et al.
International Journal of Toxicology (2025)
Closed Access
Discovery and development of COVID-19 vaccines and therapeutics: nonclinical perspectives
Nasir Ali Khan, Jean G. Sathish, Cynthia M. Rohde
The Journal of Toxicological Sciences (2024) Vol. 49, Iss. 3, pp. 79-94
Open Access | Times Cited: 1
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine
Shanti Pather, Nicola Charpentier, Frank van den Ouweland, et al.
Vaccine (2024) Vol. 42, Iss. 22, pp. 126165-126165
Open Access | Times Cited: 1
Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model
Jaehun Ahn, Jisun Lee, Gahyun Roh, et al.
Archives of Toxicology (2024)
Open Access | Times Cited: 1
Toxicologic Pathology Forum*: mRNA Vaccine Safety–Separating Fact From Fiction
Rani S. Sellers, Philip R. Dormitzer
Toxicologic Pathology (2024)
Closed Access
Are Repeat-Dose Toxicity Studies Informative for Safety Assessment of Vaccine Candidates? A Survey of Vaccine Developers
Cynthia M. Rohde, Éric Destexhe, Jan Willem van der Laan, et al.
International Journal of Toxicology (2024) Vol. 44, Iss. 1, pp. 3-11
Closed Access
Session 4: mRNA and Self-Amplifying RNA (saRNA): Opportunities for Disease Prevention and Therapy
Rani S. Sellers, Lila Ramaiah, Sue‐Jean Hong, et al.
Toxicologic Pathology (2024)
Closed Access
Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits
Jun Zhou, Christopher Bowman, Vicki R. Markiewicz, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 26-26
Open Access
Lipid Nanoparticle (LNP) Delivery Vector-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity
Liusheng Wu, Xiaoqiang Li, Xinye Qian, et al.
(2023)
Open Access | Times Cited: 1
Editorial: Immunological aspects of vaccine safety
Michael Vajdy, Barbara Rath, Kawsar R. Talaat
Frontiers in Immunology (2023) Vol. 14
Open Access
Page 1

Scroll to top